Artal Group S.A.
CIK 1053906 · View on SEC EDGAR ↗
- Portfolio value
- $931.1M
- Positions
- 2
- As of
- June 30, 2026
Portfolio value QoQ: -7.9% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 2
- Effective number of positions
- 2.0
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 5.05% Est. buys $49,012,164 · sells $235,440,000
Median holding: 7.0 quarters Tracked Q4 2024–Q2 2026 · 100.0% still held
- New positions
- 0
- Increased
- 1
- Decreased
- 1
- Closed
- 0
On this page
Performance vs S&P 500
Annualized: -5.1% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 100.0% · Options excluded: 0.0%
Sector breakdown
Full portfolio 2 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| CAVA CAVA Group, Inc. Common Stock | $510,747,055 | 54.85% | 6,507,990 | $-258,449,336 | Down ×1 | ||
| LXRX Lexicon Pharmaceuticals, Inc. - Common Stock | $420,374,549 | 45.15% | 175,156,062 | $178,988,999 | Up ×2 | ||
| No matches | |||||||